Summary for ARTG Entry:
Abbvie Pty Ltd - Tube, feeding, nasoenteral
ARTG entry for
Medical Device Included Class IIa
Abbvie Pty Ltd
Locked Bag 5029,BOTANY, NSW, 1455
ARTG Start Date
Medical Device Class IIa
- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry. Refer Part 4-5,
Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.2 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations
2002 for relevant information.
- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal
offence; and civil penalties may apply.
1 North Waukegan Road
North Chicago, IL, 60064
United States Of America
1. Tube, feeding, nasoenteral
Single Device Product
16798 Tube, feeding, nasoenteral
The AbbVie NJ is intended to provide short-term enteral access for the administration of medicine to the
small intestine. The AbbVie NJ is indicated for the administration of the medication Duodopa
(levodopa/carbidopa intestinal gel).
No Specific Conditions included on Record
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Page 1 of
Produced at 10.11.2017 at 08:04:14 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information